Eugia Pharma Specialities, a wholly-owned subsidiary of Aurobindo Pharma (NSE:AUROPHARMA, BOM:524804), has received final approval from the US Food and Drug Administration (US FDA) to manufacture and market Dasatinib Tablets, according to a Wednesday filing to the Indian stock exchanges.

The drug is bioequivalent and therapeutically equivalent to Bristol-Myers Squibb Company's reference listed drug Sprycel Tablets, which is indicated for treating chronic myelogenous leukemia and acute lymphoblastic leukemia.

The product is expected to be launched in the fiscal first quarter of financial year 2025-26.

The company's shares were up over 3% in recent trade.